Purpose of review Contrast-induced acute kidney injury (CI-AKI) is a serious complication. Although nonmodifiable and modifiable risk factors have been thoroughly characterized, the utility of the maximal allowable contrast dose (MACD) has not received adequate attention. The focus of this review is to provide a critical appraisal of this modifiable risk factor.
INTRODUCTION
Contrast-induced acute kidney injury (CI-AKI) is a serious complication following the intravenous or intra-arterial administration of iodinated contrast media. The incidence of CI-AKI is estimated at 3-19% in patients undergoing cardiovascular procedures [1] , and it confers an independent risk for adverse clinical outcomes, including increased healthcare expenditures, prolonged hospital length of stay [2] , and in-hospital mortality [3] . Once diagnosed, the clinical management of CI-AKI is largely supportive.
Nonmodifiable risk factors for CI-AKI include advanced age, diabetes mellitus, and preexisting kidney disease. Two common modifiable risk factors include extracellular fluid volume depletion and contrast agents used (type and volume) [4] . Extracellular fluid volume expansion is the cornerstone for prevention of CI-AKI [4, 5] . Intravenous fluid administration increases intravascular volume, enhances renal blood flow, and promotes diuresis. This ultimately decreases the contact duration of contrast media with the nephron, reduces activation of the renin-angiotensin-aldosterone system, and diminishes the inhibition of vasodilators. Although isotonic saline has long been considered the standard of care, sodium bicarbonate has been ]. As for pharmacological prophylaxis, some drugs have been proposed to mitigate the risk of CI-AKI by opposing vasoconstriction, enhancing renal blood flow or reducing formation of reactive oxygen species [8] .
Although no medication has been proven to have significant and consistent benefit, N-acetyl cysteine is widely used for the prevention of CI-AKI, and might exert antioxidant and vasodilatory effects [7 & ]. Statins, through their pleotropic anti-inflammatory properties, have recently been shown to be of potential benefit in this setting [5,7 & ]. However, more evidence is needed before statins can be endorsed for the prevention of CI-AKI [9] [10] [11] .
Although multiple patient-related factors increase the risk of CI-AKI, clinicians should address any modifiable risk factors, including contrast media type and volume [12] . The focus of this review is to provide a critical appraisal of one of the modifiable risk factors, contrast volume, focusing on the maximal allowable contrast dose (MACD), a concept first introduced in 1989 [13] .
CONTRAST MEDIA CONSIDERATIONS
Contrast agents are classified as ionic and nonionic [4, 6, 14, 15] (Table 1) . Ionic agents dissociate into negatively charged ions and positively charged ions. Therefore, ionic agents contain more particles per milliliter, leading to a higher osmolality compared
KEY POINTS
The contrast media volume is a modifiable risk factor for the development of CI-AKI.
Calculation of the MACD, defined empirically as 5 ml of contrast media per body weight (in kg) divided by the serum creatinine (in mg/dl), as a measure to limit the volume of contrast media, has been validated in multiple cohort studies.
Algorithms incorporating the MACD or the contrast volume to creatinine clearance or estimated GFR ratio into practice-based care bundles have been shown to reduce the incidence of CI-AKI. with nonionic agents. Nonionic agents do not dissociate but have polar hydroxyl groups that impart water solubility. All contrast agents have the basic structure of a triiodinated benzene ring (Fig. 1a) , whereas an iodine atom is attached to carbon atoms 2, 4, and 6. Carbon atoms 1, 3, and 5 are attached to different side chains, which determine the compound's solubility, osmolality, protein binding, and side effect profile. Ionic monomers were the first contrast agents to be developed and marketed. These are high-osmolar agents, with an osmolality that is five to eight times that of serum. Soon after these agents were introduced into clinical practice, it became apparent that their high osmolality could potentially cause serious adverse effects. It was hypothesized that the toxicity of contrast agents would decrease if their osmolality were reduced to approach that of serum; hence lowosmolar contrast agents were developed. Reducing the osmolality of contrast media can be achieved either by producing nonionic compounds or by joining two monomers to create a dimer (Fig. 1b) . The first low-osmolar agents to be produced were ionic dimers followed by nonionic monomers. In order to further reduce osmolality, nonionic dimers were most recently developed. Although these newer agents are iso-osmolar and least likely to cause adverse effects, a randomized control trial comparing a low-osmolar to an iso-osmolar contrast agent was not able to demonstrate a significant difference in the incidence of CI-AKI in high-risk patients [estimated glomerular filtration rate (eGFR) 20-59 ml/min/1.73 m 2 ] [16] . Regarding the pathophysiology of nephrotoxicity, contrast media generally stimulate the release of endothelin and other vasoconstrictors while simultaneously blocking the release of vasodilators such as prostaglandins and nitric oxide [4] . Highosmolar contrast agents are associated with a higher risk of CI-AKI compared with low-osmolar and iso-osmolar agents [12] , and are not used for cardiovascular procedures. This is because of the fact that high-osmolar agents dissociate into particles that induce osmotic diuresis, leading to ischemic injury and formation of reactive oxygen species. The evolution of contrast media through the reduction of osmolality has had an impact on lowering the incidence of adverse effects, including CI-AKI [12] .
CRITICAL APPRAISAL OF STUDIES EVALUATING THE UTILITY OF MAXIMAL ALLOWABLE CONTRAST DOSE
The volume of contrast administered during a cardiovascular procedure is crucial. No single, universally accepted threshold is known to cause CI-AKI. Over the years, the suggested volume cut-off has varied from a fixed volume of 125 ml [17] to a relative, weight-based volume of 3 ml/kg [18] . Low-osmolar contrast agents are widely used in clinical practice, with an observed mean administered volume ranging from 30 to 140 ml [19] . Of note, the use of low-osmolar contrast agents at a volume of greater than 30 ml has been associated with an increased incidence of CI-AKI [20] . Table 2 summarizes the main cohort studies examining the association between MACD and CI-AKI.
MACD was first conceptualized by Cigarroa et al. [13] in 1989, and defined by the following empiric formula: MACD ¼ 5 ml Â body weight (in kg)/serum creatinine (in mg/dl), with a maximum dose of 300 ml. The authors hypothesized a relationship between the contrast dose, the body weight, and the baseline kidney function, but there was no scientific basis for selecting the coefficient of 5. In this seminal but rather small single-center study, 110 patients with chronic kidney disease (baseline serum creatinine !1.8 mg/dl) deemed at increased risk for CI-AKI were included. The definition of AKI preceded standardized published definitions, and was based on an absolute increase in the serum creatinine by 1 mg/dl during the first 5 days. The authors observed a 10-fold increase in the incidence of CI-AKI among patients receiving contrast media in volumes exceeding the MACD compared with those who did not exceed the MACD (21 vs. 2%). Of note, 30 (26%) patients were excluded from the analysis as the serum creatinine was only measured for the first 2 days following the procedure. Among a subset of patients with diabetes, the incidence of CI-AKI was even higher whenever the contrast volume exceeded the MACD (38 vs. 6%). The authors concluded that among patients with diabetes and kidney disease, it may be preferable to perform angiography as a staged procedure or utilize alternative noncontrast imaging techniques to obtain the desired information rather than to exceed the MACD.
Benzene ring
Triiodinated benzene ring (a) (b) FIGURE 1. Chemical structures of the benzene ring before and after tri-iodination. Table 2 .
Cohort studies examining the association between the maximal allowable contrast dose (MACD) and development of contrast-induced acute kidney injury CI-AKI, contrast-induced acute kidney injury; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; CV, contrast volume; eGFR, estimated glomerular filtration rate; HOCM, high-osmolar contrast media; IOCM, iso-osmolar contrast media; LOCM, low-osmolar contrast media; MACD, maximal allowable contrast dose; OR, odds ratio; PVD, peripheral vascular disease; sCr, serum creatinine.
a Isotonic saline at 1 ml/kg/h for 12 h (0.5 ml/kg/h if left ventricular ejection fraction <40%).
b Isotonic saline at 1 ml/kg/h started 3-12 h before and continued to 24 h after the procedure.
This concept was validated 13 years later by Freeman et al. [21] , where both a development and a test set were derived from a multicenter registry of 16 592 percutaneous interventions to examine the association between the MACD and dialysisrequiring CI-AKI. Among the 41 (0.44%) patients who developed dialysis-requiring CI-AKI, there was a higher prevalence of diabetes mellitus, chronic kidney disease, and heart failure. Sixty-three percentage of patients who required dialysis received contrast volume that exceeded the MACD, compared with only 11% among those who did not require dialysis. After adjustment for confounding factors, the MACD was the strongest independent predictor of dialysis-requiring CI-AKI with an adjusted odds ratio (OR) of 6.2 [and a 95% confidence interval (CI) of 3.0-12.8]. Of note, this study did not mention the use of prophylactic measures to prevent CI-AKI, such as isotonic saline and N-acetyl cysteine.
In a single-center prospective cohort study by Marenzi et al. [22] , 561 patients with acute ST elevation myocardial infarction underwent percutaneous interventions and the contrast dose was left to the discretion of the interventional cardiologists. Although there was no significant difference in the prevalence of diabetes mellitus and hypertension between patients receiving contrast volume that exceeded the MACD compared with those who did not, those who exceeded the MACD had a lower mean eGFR (62 vs. 80 ml/min/1.73 m 2 ) [22] . CI-AKI was defined as a relative increase in the serum creatinine by 25% during the first 3 days following the procedure. Patients whose contrast dose exceeded the MACD had a higher incidence of CI-AKI (45 vs. 13%), and were at an increased risk for in-hospital mortality (21.4 vs. 0.9%) [22] .
In a single center prospective cohort study of 9910 patients undergoing percutaneous coronary intervention, Brown et al. [23] divided patients according to whether the contrast volume to MACD ratio was less or greater than 1 and examined the incidence of CI-AKI and other postprocedural adverse events. CI-AKI was defined as an increase in serum creatinine by at least 0.3 mg/dl or at least 50%, or dialysis requirement. The majority of patients had a baseline eGFR of more than 60 ml/ min/1.73 m 2 . Patients in whom the contrast volume did not exceed the MACD had a lower prevalence of hypertension, heart failure and coronary artery disease, and more preserved eGFR. The administration of contrast volume that exceeded the MACD was an independent risk factor for CI-AKI, and there was a linear increase in the unadjusted risk with higher contrast volume (13, 20 , and 27% for a contrast volume to MACD ratio of 1.0-1.5, 1.5-2.0, and >2.0, respectively). Furthermore, the adjusted odds ratio for CI-AKI was 1.60, 2.02, and 2.94 following exposure to a contrast volume to MACD ratio of 1.0-1.5, 1.6-2.0, and > 2.0, respectively. Patients who received a contrast volume to MACD ratio of greater than 1 had higher rates of AKI requiring dialysis (1.5 vs. 0.2%), cardiac events (13.4 vs. 10.2%), bleeding complications (8.4 vs. 4.1%), and in-hospital death (3.4 vs. 1.7%) [23] .
In a retrospective cohort study, Ogata et al. [24] analyzed 100 patients with advanced stage-4 chronic kidney disease (baseline eGFR < 30 ml/ min/1.73 m 2 ) who had undergone elective percutaneous coronary intervention. The authors stratified patients according to the contrast volume to eGFR ratio and the MACD, and divided them into three mutually exclusive groups: a low-dose group (contrast volume to eGFR ratio <1), a medium-dose group (contrast volume to eGFR ratio >1 but <MACD), and a high-dose group (contrast volume >MACD) [24] . Baseline characteristics were well balanced between the three groups. The incidence rate of CI-AKI, as defined by an increase in serum creatinine by 0.5 mg/dl or 25% 48 h following the procedure, occurred in 11% of patients, was 0, 11, and 23% in the low-dose, medium-dose, and highdose group, respectively. Furthermore, the rate of the composite outcome of dialysis requirement, myocardial infarction or death increased from 0 to 14, and 31% in the three respective groups [24] . The authors concluded that among patients with advanced CKD, aiming for a contrast volume to eGFR ratio of less than 1 might reduce the incidence of CI-AKI and achieve better clinical outcomes following elective percutaneous coronary intervention.
Raposeiras-Roubín et al. [25] performed a retrospective cohort study of 940 patients with acute coronary syndrome undergoing coronary angiography, in an effort to establish a safe contrast dose based on the absolute and relative contrast volume using the MACD and the contrast volume to eGFR ratio, and develop a simple strategy for contrast dosing. CI-AKI, defined by an increase in the serum creatinine by 0.5 mg/dl within 72 h, developed in 54 (5.7%) patients. The incidence of CI-AKI was higher whenever the contrast volume exceeded the MACD (36.1 vs. 3.6%). Moreover, every 10 ml increase in contrast volume was associated with a 5% increase in the risk of CI-AKI. The cut-off level for the absolute contrast volume with greatest discriminative power was 158 ml, with a sensitivity and specificity of 74 and 52%, respectively. The authors also found that using a contrast volume exceeding 50% of the MACD as a predictor cut-off point had a sensitivity and specificity of 74.1 and 65.6%, respectively. Furthermore, every 0.1 U increase in the contrast volume to eGFR ratio was associated a 4.9% increased risk of CI-AKI, and the cut-off level with greatest discriminative power was 2.7, with a sensitivity and specificity of 74.1 and 64.6%, respectively. The authors proposed a two-step algorithm to stratify the risk of CI-AKI according to the MACD and the contrast volume to eGFR ratio (Fig. 3) . The authors found that their proposed algorithm had a higher positive predictive value than the Mehran risk score (40.7 vs. 8.8%) with similar sensitivity (90.7 vs. 83.3%). This proposed two-step algorithm requires further study and external validation.
Laskey et al. [26] examined an unselected cohort of 3179 consecutive patients undergoing percutaneous coronary intervention, and found that a contrast volume to creatinine clearance ratio of greater than 3.7 was a fair discriminator for predicting CI-AKI, as defined by an increase in serum creatinine by more than 0.5 mg/dl within 48 h, and was independently associated with development of CI-AKI with an odds ratio of 3.84.
In a multicenter cohort study of 58 957 patients undergoing cardiovascular procedures, Gurm et al. [27] found that the contrast volume to creatinine clearance ratio performed significantly better than the MACD at predicting CI-AKI. Moreover, a contrast volume to creatinine clearance ratio cut-off of more than 3 was associated with an adjusted odds ratio of 1.46 for CI-AKI, and of 1.89 for dialysis requirement. The authors concluded that this ratio should be less than 2 and not exceed 3 for any angiographic procedure. Figure 2 displays the incidence rate of CI-AKI observed in the above-mentioned observational studies among patients who received contrast volume that did or did not exceed the MACD. The observed variable rates suggest significant heterogeneity amongst the studies, including variable study design, sample size, AKI definition, preexisting comorbidities, and implemented preventive measures. In these observational studies, the 'contrast volume' variable suffers from confounding by indication as patients undergoing emergent rather than elective percutaneous coronary interventions were more likely to be hemodynamically unstable and require greater contrast volume (i.e. for coronary angioplasty and insertion of stents). Nevertheless, all these observational studies point to the fact that modulating the contrast volume is a potentially modifiable risk factor for CI-AKI, and a measure of excessive contrast volume (e.g. MACD or contrast volume to eGFR ratio) needs to be determined a priori by the operator, and ideally not exceeded during a cardiovascular procedure.
OTHER IMPORTANT CONSIDERATIONS RELATED TO CONTRAST MEDIA
The route of administration is another important consideration as contrast media is more nephrotoxic whenever administered intra-arterially [28, 29] . This effect is hypothesized to be due in part to a higher intra-renal concentration of contrast media achieved acutely after intra-arterial rather than intravenous injection, and to potential renal atheroembolic disease, which can occur in the setting of intra-arterial instrumentation. This question has not been properly examined and requires further study.
Furthermore, the use of a transfemoral (Seldinger technique) or transradial (Sones technique) approach to cardiac catheterization might affect the risk of postprocedure AKI. Periprocedural bleeding, especially retroperitoneal bleeding in the setting of a transfemoral approach, is an emerging risk factor for the development of postprocedural AKI, and the transradial access has been associated with a lower incidence of vascular access-related bleeding complications and all-cause mortality in a large randomized controlled trial of 8404 patients with acute coronary syndrome [30] , and a lower risk of postprocedural AKI in a large meta-analysis of more than 12 000 patients with an average incidence rate of 10.3 vs. 4.6% [31] . These studies call for the more widespread use of the transradial approach to cardiac catheterization, whenever technically feasible, which might also minimize the risk of renal atheroembolic disease as wires would not traverse the abdominal aorta.
CALL FOR REFINEMENT OF CONTRAST-INDUCED ACUTE KIDNEY INJURY PREDICTION MODELS
The reliability of both the absolute and relative contrast volume as a modifiable risk factor and independent predictor of AKI call for the refinement of existing prediction models for CI-AKI. The Mehran risk score, published more than a decade ago, was developed to predict AKI following percutaneous coronary intervention, and has been widely adopted [32] . For this risk prediction tool, points are given for hypotension, use of intra-aortic balloon pump, congestive heart failure, age more than 75, anemia, volume of contrast, and serum creatinine (>1.5 mg/dl). A recently developed risk prediction tool incorporates additional risk factors such as acute coronary syndrome, urgent catheterization, history of prior AKI, use of loop diuretics, and hypoalbuminemia [33] . Novel risk scores should consider the incorporation of the MACD, proteinuria, an important marker of kidney damage that is a known risk factor for AKI independent of eGFR [34] , and use of blockers of the renin-angiotensin-aldosterone system (RAAS), which have also been associated with an increased risk of CI-AKI [35] .
CURRENT CLINICAL PRACTICE GUIDELINES FOR PREVENTION OF CONTRAST-INDUCED ACUTE KIDNEY INJURY
For the prevention of CI-AKI, the 2011 ACCF/AHA/ SCAI Guideline for Percutaneous Coronary Intervention state that patients should be assessed for risk of CI-AKI prior to the procedure; patients undergoing cardiac catheterization with contrast media should receive adequate preparatory hydration; and in patients with CKD (creatinine clearance <60 ml/ min), the volume of contrast media should be minimized [36] . Similarly, the 2012 KDIGO Clinical Practice Guidelines on AKI focus on other measures to prevent CI-AKI following angiographies. These measures include the use of biplane, avoidance of test injections, unnecessary projections, and ventriculography, use of isotonic contrast-media for renal artery injections, use of CO 2 in venous and below diaphragm for arterial procedures, use of selective catheterizations whenever appropriate, and reducing aortic flow and contrast medium volume by temporal occlusion of femoral arteries with tourniquets whenever performing aortography [37 & ]. Future guidelines for prevention of CI-AKI following percutaneous coronary intervention should consider incorporating a more objective measure of contrast media volume such as the MACD or the contrast volume to creatinine clearance ratio, and promote the staging of procedures whenever appropriate, and promote the transradial arterial catheterization method as the default approach.
The National Quality Forum has defined CI-AKI as a patient safety measure, and has issued a safe practice guideline aimed at reducing the contrast medium-related adverse events [38] . Furthermore, the Center of Medicare & Medicaid Services recently proposed the addition of CI-AKI as a new condition to the list of hospital-acquired conditions; this condition will be subject to reduced payment provisions under the Inpatient Prospective Payment System, nevertheless, this measure has not yet been released [39] . We also propose that CI-AKI should become a hospital-based quality of care indicator with payper-performance ramifications, and call for systemwide implementation of evidence-based care bundles to prevent CI-AKI. The approach should be similar to what has been implemented across acute care hospitals in the United States to reduce morbidity and mortality, such as the central line, ventilator, and sepsis management bundles promoted by the Institute for Healthcare Improvement [40] . In high-risk populations, CI-AKI prevention bundles should incorporate hydration with isotonic saline or sodium bicarbonate prior to contrast administration, the temporary discontinuation of RAAS blockers, the use of low-osmolar or iso-osmolar contrast agents, and the minimization of contrast volume. Figure 3 provides a two-step algorithm that incorporates the MACD and the contrast volume to eGFR ratio, as an approach to minimize contrast volume.
INCORPORATING THE MAXIMAL ACCEPTABLE CONTRAST DOSE INTO PRACTICE-BASED CARE BUNDLES TO PREVENT CONTRAST-INDUCED ACUTE KIDNEY INJURY: LESSONS LEARNED FROM QUALITY IMPROVEMENT REPORTS
The Blue Cross Blue Shield of Michigan Cardiovascular Consortium reported on a demonstration project aimed at reducing the incidence of CI-AKI following percutaneous coronary intervention [41] . In this quality improvement report that included five hospitals, patients were deemed at high risk for CI-AKI if they had diabetes, a serum creatinine at least 2 mg/dl, peripheral vascular disease, heart failure, or cardiogenic shock. The consortium proposed management guidelines including the use of aggressive intravenous hydration and consideration for N-acetyl cysteine; determining the MACD and not exceeding it by performing biplanar coronary angiography and avoiding unnecessary images; considering staged procedures (several days after the first procedure); the use of small catheters to limit contrast volume; and the use of low-osmolar contrast agents. There was a baseline assessment period and an intervention period, and workgroup meetings focused on selection of quality indicators, use of bedside tools for quality improvement and risk assessment (i.e. use of the MACD), site visits, and feedback on outcomes. Over a 4-year period, the percentage of cases exceeding the MACD steadily declined, and this was paralleled by a progressive decline in the incidence of CI-AKI. The study demonstrates that the implementation of a regional continuous quality improvement program is feasible and by enhancing adherence to quality of care indicators, outcomes of percutaneous coronary intervention can be improved. This calls for the implementation of such evidence-based care bundles to prevent CI-AKI.
The Northern New England Cardiovascular Disease Study Group led a regional quality improvement effort to achieve a cost-effective and sustainable decrease in the incidence of CI-AKI [42] . This quality improvement project was conducted over 6 years and constituted six hospitals. Multidisciplinary teams with key stake holders developed interventions with a focus on oral hydration before and after the procedure, preprocedural standardization of intravenous fluid administration, reducing the fasting period from 12 to 2-4 h, minimizing contrast volume administration by calculating the MACD prior to every procedure, and respecting it by limiting contrast media administration during the procedure. The authors reported a 21% (95% CI 7-33%) decrease in the rate of CI-AKI after the intervention. Some of the key barriers to implementation included resistance to amend physician orders that were based on older protocols [42] .
CONCLUSION
In conclusion, prevention of CI-AKI must remain a clinical priority because of the short-term associated morbidity and mortality, and the long-term risk of decline in kidney function [43] . In addition to identifying high-risk patients based on their comorbidities and preprocedural hydration and possible use of N-acetyl cysteine, additional intraprocedural preventive measures (Table 3) should include a priori calculation of the MACD and contrast volume to creatinine clearance or eGFR ratio to limit contrast volume, the adoption of the transradial approach, the use of small catheters to limit contrast volume, the use of low-osmolar and iso-osmolar contrast agents, and whenever indicated, the use of staged procedures. . Two-step algorithm to stratify risk of contrastinduced acute kidney injury (CI-AKI) according to the maximal acceptable contrast dose (MACD) and the contrast volume to the estimated glomerular filtrate rate ratio (CV/eGFR). Modified from reference [25] . 
